For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $141.43 in the prior trading day, Biogen Inc (NASDAQ: BIIB) closed at $141.38, down -0.04%. In other words, the price has decreased by -$0.04 from its previous closing price. On the day, 0.97 million shares were traded. BIIB stock price reached its highest trading level at $142.88 during the session, while it also had its lowest trading level at $140.91.
Ratios:
Our goal is to gain a better understanding of BIIB by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.71 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.60. For the most recent quarter (mrq), Quick Ratio is recorded 0.90 and its Current Ratio is at 1.35. In the meantime, Its Debt-to-Equity ratio is 0.40 whereas as Long-Term Debt/Eq ratio is at 0.29.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Bernstein on February 11, 2025, initiated with a Mkt Perform rating and assigned the stock a target price of $160.
On January 02, 2025, Piper Sandler Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $315 to $138.
BMO Capital Markets Downgraded its Outperform to Market Perform on December 20, 2024, whereas the target price for the stock was revised from $230 to $164.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 07 ’25 when SHERWIN STEPHEN A sold 8,760 shares for $150.02 per share. The transaction valued at 1,314,142 led to the insider holds 11,318 shares of the business.
STEPHEN A SHERWIN bought 8,760 shares of BIIB for $1,290,961 on Mar 07 ’25. On Dec 09 ’24, another insider, Singhal Priya, who serves as the Head of Development of the company, sold 110 shares for $157.21 each. As a result, the insider received 17,293 and left with 5,426 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIIB now has a Market Capitalization of 20694499328 and an Enterprise Value of 25036187648. As of this moment, Biogen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.64, and their Forward P/E ratio for the next fiscal year is 8.99. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.23 while its Price-to-Book (P/B) ratio in mrq is 1.23. Its current Enterprise Value per Revenue stands at 2.587 whereas that against EBITDA is 8.357.
Stock Price History:
The Beta on a monthly basis for BIIB is 0.04, which has changed by -0.35176528 over the last 52 weeks, in comparison to a change of 0.08190584 over the same period for the S&P500. Over the past 52 weeks, BIIB has reached a high of $238.00, while it has fallen to a 52-week low of $128.51. The 50-Day Moving Average of the stock is -1.03%, while the 200-Day Moving Average is calculated to be -21.72%.
Shares Statistics:
The stock has traded on average 1.57M shares per day over the past 3-months and 1751760 shares per day over the last 10 days, according to various share statistics. A total of 145.80M shares are outstanding, with a floating share count of 145.62M. Insiders hold about 0.51% of the company’s shares, while institutions hold 90.99% stake in the company. Shares short for BIIB as of 1740700800 were 3719971 with a Short Ratio of 2.37, compared to 1738281600 on 3741109. Therefore, it implies a Short% of Shares Outstanding of 3719971 and a Short% of Float of 2.87.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Current recommendations for the stock of the company come from 23.0 analysts. The consensus estimate for the next quarter is $4.1, with high estimates of $4.82 and low estimates of $3.73.
Analysts are recommending an EPS of between $17.4 and $14.08 for the fiscal current year, implying an average EPS of $15.84. EPS for the following year is $15.77, with 27.0 analysts recommending between $18.96 and $12.03.
Revenue Estimates
24 analysts predict $2.25B in revenue for the current quarter. It ranges from a high estimate of $2.42B to a low estimate of $2.16B. As of the current estimate, Biogen Inc’s year-ago sales were $2.29BFor the next quarter, 24 analysts are estimating revenue of $2.32B. There is a high estimate of $2.46B for the next quarter, whereas the lowest estimate is $2.27B.
A total of 30 analysts have provided revenue estimates for BIIB’s current fiscal year. The highest revenue estimate was $9.5B, while the lowest revenue estimate was $8.97B, resulting in an average revenue estimate of $9.17B. In the same quarter a year ago, actual revenue was $9.68BBased on 30 analysts’ estimates, the company’s revenue will be $9.18B in the next fiscal year. The high estimate is $10.14B and the low estimate is $8.6B.
